Join us for a virtual KOL event with Nuvectis Pharma, featuring Bradley J. Monk, MD, FACS, FACOG (University of Arizona College of Medicine) and Ramez N. Eskander, MD (University of California San Diego) who will discuss the unmet medical need for patients with ovarian cancer, along with the opportunity for precision medicine program, NXP800, a small-molecule GCN2 kinase activator, in the current treatment landscape.

NXP800 was granted Fast Track Designation by the U.S. Food and Drug Administration (“FDA”) for the treatment of platinum-resistant, AT-rich interactive domain-containing protein 1a (ARID1a)-mutated, ovarian carcinoma.

Gordon Mills, MD, PhD (Knight Cancer Institute, OHSU) will highlight the 2nd precision drug candidate NXP900, a small-molecule, potent and selective SRC/YES1 kinase inhibitor. The Investigational New Drug Application (IND) for NXP900 has been cleared by the FDA and the Phase 1a study is pending commencement.

A live question and answer session will follow the formal presentations.